ClinicalTrials.gg
CompletedNCT04173793Updated Mar 2, 2023

A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

A Phase 2 interventional study of AK102 and Placebo in Heterozygous Familial Hypercholesterolemia, sponsored by Akeso. Completed at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-02.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Hyperlipoproteinemia Type II with a site in China — 13 open to participants now, 14 under way, 8 of them phase 3. Hyperlipoproteinemia Type II · China.

Enrollment
14th of 22
109 · median 142
Started
2019
with 1 other
Phase 2
3 of 24
1 open now
Registered
2nd of 24
by date
Lead sponsor
1 of 24
Akeso

Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, this one is the 14th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2019, is one of 3 in phase 2, and was the 2nd registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

13 of the 24 studies in Hyperlipoproteinemia Type II with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hyperlipoproteinemia Type II with a site in China, or all of them as a file.
02

Study summary

This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of AK102 in patients with heterozygous familial hypercholesterolemia (HeFH).The primary objective of this study is to evaluate the efficacy of AK102 in patients with HeFH.

03

Conditions studied

  • Heterozygous Familial Hypercholesterolemia

Keywords

  • HeFH
  • LDL-C
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subjects with heterozygous familial hypercholesterolemia diagnosed by genetic confirmation or clinical diagnosis criteria.
  • Stable on pre-existing, lipid-lowering therapies (statins with or without ezetimibe) for at least 4 weeks with no planned medication or dose change for the duration of study participation.
  • Fasting Low-Density Lipoprotein Cholesterol (LDL-C) ≥ 70 mg/dL in patients with history of Atherosclerotic Cardiovascular Disease (ASCVD) or Fasting Low-Density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL in patients without history of Atherosclerotic Cardiovascular Disease (ASCVD).
  • Fasting triglycerides ≤ 400 mg/dL.
  • Body weight ≥ 40kg.

Key Exclusion Criteria:

  • Subjects with homozygous FH (clinically or by genotyping).
  • Receipt of LDL apheresis within 12 months prior to the first dose of product.
  • Receipt of Lomitapide or Mipomersen within 5 months prior to the first dose of Investigational product.
  • Prior use of PCSK9 inhibitors.
  • Creatine kinase (CK) >3 times of the (ULN).
  • (AST) ≥ 2 x ULN.
  • Estimated (eGFR)≤ 30 mL/min/1.73m\^2.
  • Thyroid-Stimulating Hormone (TSH)> 1.5 x ULN or \<1 x LLN.
  • Type 1 diabetes, or type 2 diabetes that is or poorly controlled(> 8.5%).
  • Subjects with untreated or active chronic or active virus infections.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    AK102 450 mg

    Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks

    Drug: AK102 · Drug: Statins and/or Ezetimibe

  • Experimental
    AK102 300 mg

    Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks

    Drug: AK102 · Drug: Statins and/or Ezetimibe

  • Experimental
    AK102 150 mg

    Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks

    Drug: AK102 · Drug: Statins and/or Ezetimibe

  • Placebo comparator
    Placebo Q4W

    Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks

    Drug: Placebo · Drug: Statins and/or Ezetimibe

  • Placebo comparator
    Placebo Q2W

    Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks

    Drug: Placebo · Drug: Statins and/or Ezetimibe

Interventions

  • DrugAK102

    Administered by subcutaneous injection

  • DrugPlacebo

    Administered by subcutaneous injection

  • DrugStatins and/or Ezetimibe

    Drug pages: Statins · Ezetimibe

    Lipid-lowering therapies

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 12

    Time frame: At baseline and week 12

Secondary outcomes

  1. Percent change from baseline in low-density lipoprotein cholesterol (LDL-C)

    Time frame: From baseline through 12 weeks

  2. Percent change from baseline in high-density lipoprotein cholesterol (HDL-C)

    Time frame: From baseline through 12 weeks

  3. Percent change from baseline in non High-density lipoprotein (non-HDL) cholesterol

    Time frame: From baseline through 12 weeks

  4. Percent change from baseline in serum Triglyceride (TG) cholesterol

    Time frame: From baseline through 12 weeks

  5. Percent change from baseline in Apolipoprotein B (Apo B)

    Time frame: From baseline through 12 weeks

  6. Percent change from baseline in Apolipoprotein A-I (ApoA-I)

    Time frame: From baseline through 12 weeks

  7. Percent change from baseline in Lipoprotein(a) [Lp-(a)]

    Time frame: From baseline through 12 weeks

  8. Percent change from baseline in Total Cholesterol(TC)

    Time frame: From baseline through 12 weeks

  9. Incidence of treatment-emergent adverse events

    Time frame: From baseline through 12 weeks

  10. Serum concentrations of AK102

    Time frame: From baseline through 12 weeks

  11. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    The immunogenicity of AK102 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies.

    Time frame: From baseline through 12 weeks

  12. Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9)

    Time frame: From baseline through 12 weeks

07

Study locations

2 sites
  • Beijing Anzhen Hospital
    Beijing, Beijing 100029, China
  • Peking Union Medical College Hospital
    Beijing, 100000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Sep 2022, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2019
First posted
Nov 22, 2019
StartActual
Nov 18, 2019
Primary completionActual
Sep 26, 2022
CompletionActual
Sep 26, 2022
Last update
Mar 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04173793
Lead sponsor
Akeso
Collaborators
AD Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Nov 22, 2019
Start date
Nov 18, 2019
Primary completion
Sep 26, 2022
Completion
Sep 26, 2022
Last update
Mar 2, 2023

Study contacts

Shuyang Zhang, MD
principal investigator · Peking Union Medical College Hospital
Yujie Zhou, MD
principal investigator · Beijing Anzhen Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ebronucimab

Start the discussion